29176-90-7

Usage

Uses

Used in Pharmaceutical Research:
(5-CHLORO-2-OXO-BENZOOXAZOL-3-YL)-ACETIC ACID is used as a building block for the development of pharmaceuticals targeting various diseases and conditions. Its ability to interact with biological targets and modulate their activity makes it a promising candidate for creating novel therapeutic agents.
Used in Drug Discovery:
In the field of drug discovery, (5-CHLORO-2-OXO-BENZOOXAZOL-3-YL)-ACETIC ACID serves as a valuable tool due to its potential to engage with biological targets. This interaction aids researchers in identifying new therapeutic pathways and developing innovative treatments for a range of health issues.
Used in Medicinal Chemistry:
(5-CHLORO-2-OXO-BENZOOXAZOL-3-YL)-ACETIC ACID is utilized as a key component in medicinal chemistry, where it contributes to the design and synthesis of new drugs. Its unique structure and properties facilitate the creation of compounds with enhanced efficacy and selectivity, ultimately leading to more effective treatments for various medical conditions.
Used in Drug Development:
(5-CHLORO-2-OXO-BENZOOXAZOL-3-YL)-ACETIC ACID plays a crucial role in drug development, as it helps researchers understand the molecular mechanisms underlying various diseases. This knowledge is essential for designing targeted therapies that can specifically address the root causes of these conditions, leading to more effective and personalized treatments.

Upstream product

• 95-85-2 2-hydroxy-5-chloro-aniline 
• 95-25-0 5-chloro-2-benzoxazolinone 
• 29176-91-8 ethyl 2-[5-chloro-2-oxobenzo[d]oxazole-2(3H)-yl]acetate 

Downstream Products

• 863723-70-0 C₁₆H₁₃ClN₂O₃ 
• 1003875-25-9 N-[1-(4-biphenylyl)-1-methyl-2-(1-pyrrolidinyl)ethyl]-2-(5-chloro-2-oxo-1,3-benzoxazol-3(2H)-yl)-N-methylacetamide 

Relevant academic research and scientific papers

Benzooxazolone or benzothiazolone derivatives preparation method therof, and pharmaceutical composition for use in preventing or treating Urotensin-Ⅱ receptor activity related diseases containing the same as an active ingredient

The present invention relates to benzoxazolone and benzothiazolone derivatives or a pharmaceutically acceptable salt thereof, a producing method thereof, and a pharmaceutical composition for preventing or treating urotensin-II receptor activity-related diseases containing the same as an active ingredient. Benzoxazolone and benzothiazolone derivatives act as an antagonist of a urotensin-II receptor, and thus can be usefully used for preventing or treating urotensin-II receptor activity-related diseases such as congestive heart failure, heart ischemia, myocardial infarction, cardiomegalia, myofibrosis cordis, coronary artery disease, arteriosclerosis, hypertension, asthma, renal failure, diabetes, vascular inflammation, degenerative neuronal disease, stroke, pain, depression, mental illness, and cancer.COPYRIGHT KIPO 2016

HETEROCYCLIC ACETAMIDE COMPOUND

[Problem] A compound which is useful as a dopamine D1 receptor positive allosteric modulator (D1 PAM) is provided. [Means for Solution] The present inventors have studied a compound which has a dopamine D1 receptor positive allosteric modulating activity and is useful as an active ingredient of a pharmaceutical composition for preventing and/or treating cognitive impairment, negative symptoms of schizophrenia, Parkinson's disease, Alzheimer's disease, Huntington's disease, drug addictions, or the like, and they have thus found that a heterocyclic acetamide compound has a dopamine D1 receptor positive allosteric modulating activity, thereby completing the present invention. The heterocyclic acetamide compound of the present invention has a dopamine D1 receptor positive allosteric modulating activity and can be used as an agent for preventing and/or treating cognitive impairment, negative symptoms of schizophrenia, Parkinson's disease, Alzheimer's disease, Huntington's disease, drug addictions, or the like.

Development of potent and selective small-molecule human Urotensin-II antagonists

This work describes the development of potent and selective human Urotensin-II receptor antagonists starting from lead compound 1, (3,4-dichlorophenyl)methyl{2-oxo-2-[3-phenyl-2-(1-pyrrolidinylmethyl)-1-piperidinyl]ethyl}amine. Several problems relating to oral bioavailability, cytochrome P450 inhibition, and off-target activity at the kappa opioid receptor and cardiac sodium channel were addressed during lead development. hUT binding affinity relative to compound 1 was improved by more than 40-fold in some analogs, and a structural modification was identified which significantly attenuated both off-target activities.

NOVEL HETEROCYCLIC COMPOUND

A drug having a high affinity for benzodiazepine ω3 receptors and showing curative and preventive effects for anxiety and depression, which comprises as the active ingredient, for example, a compound of the formula (1): wherein R1 an

Inhibition of nitric oxide synthase by benzoxazolones

A series of benzoxazolones has been synthesized using modifications of literature methods. The synthetic benzoxazolone analogs, along with commercially available analogs, were evaluated as inhibitors of nitric oxide synthases (NOS). Structure-activity relationships are also discussed.